Diabetes Obes Metab 2019;21:10371042 Bezin J, Gouverneur A, Pnichon M, Mathieu C, Garrel R, Hillaire-Buys D, Pariente A, Faillie JL
[PMC free article: PMC11519213] [PubMed: 39103719] 368
It remains to be further investigated, whether it is possible to avoid blunting of the inhibitory action by other types of inhibitors, by their combination or by combination of the diverse therapeutic modalities to efficiently limit propagation of tumor cells
Compared with people taking another class of diabetes drugs -- GLP1 receptor agonists -- those taking the SGLT2 drugs had 36 percent reduced odds of developing gout, the painful condition that usually starts in the foot
Future research should further investigate the optimal combinations, dosages, and delivery methods of antioxidants to optimize interventions for reproductive health in diabetic patients and advance personalized precision medicine
Int J Gynecology Obstetrics